CSIMarket


Singular Genomics Systems Inc   (OMIC)
Other Ticker:  
 


 

Singular Genomics Systems Inc

OMIC's Financial Statements and Analysis



Singular Genomics Systems Inc narrowed third quarter of 2023 net loss per share of $-0.31 compare to net loss per share of $-0.33 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.35 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.31 $  0 Mill
$+0.02     Unch.    



Singular Genomics Systems Inc 's Revenue rose by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by -8.51 % sequentially.


Singular Genomics Systems Inc is

More on OMIC's Income Statement



Singular Genomics Systems Inc 's in thethird quarter of 2023 recorded net loss of $-22.360 million, an improvement compare to net loss of $-23.790 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-25.578 million realized in previous quarter.

More on OMIC's Growth

Singular Genomics Systems Inc Inventories
Inventories declined by -19.64 % to $13.42 million from III. Quarter a year ago, sequentially inventories fell by -6.51 %. In Sep 30 2023 company's net cash and cash equivalents decreased by $-42 million, capital expenditures grew by -1.127-90.24%, to $0 millions compare to same quarter a year ago

More on OMIC's Cash flow Statement


Singular Genomics Systems Inc does not pay out common stock dividend.

In trailing twelve-month period Singular Genomics Systems Inc payed $ -1.02 cash per share, on a free-cash flow basis .

Book value fell by -9.70 % sequentially to $2.72 per share.
Tangible Book value fell to $ 2.72 per share from $ 3.01.

Company issued 0.67 million shares or 0.92 % in Sep 30 2023.
Debt Coverage Ratio was 8.07.

More on OMIC's Dividends

 Market Capitalization (Millions) 37
 Shares Outstanding (Millions) 73
 Total Debt (Millions $) 10
 Revenue (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) 89
 Cash Flow (TTM) (Millions $) -60
 Capital Exp. (TTM) (Millions $) -2
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Singular Genomics Systems Inc does not pay out common stock dividend.

In trailing twelve-month period Singular Genomics Systems Inc had negative $ -1.02 cash flow per share, on a free-cash flow basis .

Book value fell by -9.70 % sequentially to $2.72 per share.
Tangible Book value fell to $ 2.72 per share from $ 3.01.

Company issued 0.67 million shares or 0.92 % in Sep 30 2023.
Debt Coverage Ratio was 8.07.

More on OMIC's Balance Sheets

 Market Capitalization (Millions) 37
 Shares Outstanding (Millions) 73
 Total Debt (Millions $) 10
 Revenue (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) 89
 Cash Flow (TTM) (Millions $) -60
 Capital Exp. (TTM) (Millions $) -2
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Singular Genomics Systems Inc Earnings

Singular Genomics Systems Inc Struggles with Dismal Revenue and Inventory Decline in Q3 2023



The Laboratory Analytical Instruments company, Singular Genomics Systems Inc, reported limited revenue of only $0.462 million in the third quarter of 2023. Moreover, the company experienced a net loss of an alarming $-22.360 million in the same quarter, a significant deterioration compared to the previous year's deficit of $-23.790 million. Furthermore, inventories have declined to $13.4 million, indicating potential weakening future demand. These factors, coupled with other concerning indicators, suggest a bearish outlook for Singular Genomics Systems Inc.
Declining Inventories Reflect Lower Demand:
A critical aspect to assess a company's growth prospects lies in its inventory levels, whic...

Singular Genomics Systems Inc Faces Financial Crisis with Only $0.505 Million in Revenue and Growing Net Loss in Q2 2023

In the latest fiscal time-frame ending June 30th, 2023, Singular Genomics Systems Inc, a prominent player in the industry, has reported disappointing financial results. With only $0.505 million in revenue, one can clearly see that the company is struggling to generate substantial income. This represents a significant decline compared to the same period a year ago.
To make matters worse, Singular Genomics Systems Inc also experienced a considerable net loss of $-25.578 million during the fiscal time-frame, which is even larger than the loss of $-23.982 million reported in the previous year. This alarming trend raises concerns about the company's ability to manage its expenses effectively and generate prof...

Singular Genomics Systems Inc Shows Promising Growth Potential with Revenue of $0.863 Million in Latest Financial Report

Singular Genomics Systems Inc is setting the stage for incredible growth and profitability within the biotechnology and pharmaceuticals industry. While the company recorded a net deficit of $-23.633 million in the first quarter of 2023 earnings season, the substantial improvement in Return on Equity (ROE) compared to Q4 2022 is a clear indication of the company's progress towards reaching its financial goals.
As per the recent financial report released by the company, Singular Genomics Systems Inc disclosed revenue of $0.863 million, which is an impressive figure in itself. While some skeptics may point towards the net deficit of the company, it is essential to note that Singular Genomics Systems Inc is ...


Date modified: 2023-11-16T18:32:53+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com